1-6 of 6
Jacqueline Bussolari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)

Free
Mahipal Suraneni, Da Yin, Dianna Wu, Daksh Thaper, Shajo Kunnath-Velayudhan, Jianmei Wu, Alfredo Perales Puchalt, Melissa Beelen, Julie Larsen, Leen Slaets, Arnob Banerjee, Donne Bennett Caces, Jacqueline Bussolari, Luke Mountjoy, Joanna Rhodes, Jacob Christensen, Martin Hutchings, Matthew Ku, Krish Patel, Vicki Plaks
Journal: Blood
Blood (2025) 146 (Supplement 1): 568.
https://doi.org/10.1182/blood-2025-568
Published: 2025
Journal Articles

Estimating the United States cure-adjusted prevalence of diffuse large B-cell lymphoma (DLBCL): An epidemiological model

Free
Mahmoud Hashim, Tara Beaulieu, Jackie Kwong, Jacqueline Bussolari, Mike Spencer, Maren Gaudig
Journal: Blood
Blood (2025) 146 (Supplement 1): 1885.
https://doi.org/10.1182/blood-2025-1885
Published: 2025
Journal Articles

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

Free
John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, MD, Bruno Martino, MD, Dietger Niederwieser, MD, Andreas Reiter, MD, Bart L Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Jacqueline Bussolari, PhD, Eugene Zhu, PhD, Fei Huang, PhD, Esther Rose, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye M. Feller, MD, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 685.
https://doi.org/10.1182/blood-2018-99-115163
Published: 2018
Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Free
David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux
Journal: Blood
Blood (2018) 132 (Supplement 1): 463.
https://doi.org/10.1182/blood-2018-99-114877
Published: 2018
Journal Articles

Characterization of Disease, Treatment Patterns, and Outcomes of Patients with Myelofibrosis: Analysis of 2 United States Commercial Claims Databases

Free
Maneesha Mehra, Ravi Potluri, Jianming He, Grace Wang, Suneel Mundle, Jacqueline Bussolari
Journal: Blood
Blood (2016) 128 (22): 4769.
https://doi.org/10.1182/blood.V128.22.4769.4769
Published: 2016
Journal Articles

Transfusion Burden and Outcomes in Patients with Low- or Unspecified-Grade Myelodysplastic Syndromes Treated with Erythropoiesis-Stimulating Agents: Analysis of a United States Commercial Claims Database

Free
Maneesha Mehra, Ravi Potluri, Jianming He, Aleksandra Rizo, Suneel Mundle, Jacqueline Bussolari
Journal: Blood
Blood (2016) 128 (22): 5974.
https://doi.org/10.1182/blood.V128.22.5974.5974
Published: 2016